Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2019 Miami Breast Cancer Conference
Oncology Conference Multimedia
View more videos >>
Dr. Rugo on 20-Year Span of Breast Cancer Advancements
Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast Cancer
Dr. Mittendorf on FDA Approval of Frontline Atezolizumab/Nab-Paclitaxel in PD-L1+ TNBC
Oncology Conference Articles
CTC Surveillance in Early-Stage Breast Cancer: What's Next?
Blood-based biomarkers offer great potential for use in the management of breast and other cancers.
A New Trio of Genes Enters the Risk Assessment Equation in Hereditary Breast Cancer
David M. Euhus, MD, discusses a new trio of genes entering the risk assessment equation in hereditary breast cancer.
Experts Say DCIS Requires Focus on Genomics and Microenvironment
Identifying patients with ductal carcinoma in situ who are more likely to develop invasive breast cancer remains a challenge, despite decades of research and the development of stratification methods to predict progression and recurrence.
New Strategies Shift Landscape in HR+ Metastatic Breast Cancer
There has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.
Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer
CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.
Bridging the Knowledge Gap Between Biosimilars and Biologics in Breast Cancer
Since 2006, the European Medicines Agency has granted marketing authorization for more than 40 biosimilars, and, in less than 4 years, the FDA has approved 17, yet the knowledge gap in the understanding of biosimilarity poses a unique challenge to the agents’ assimilation into clinical practice and possible impact on access and cost savings, experts say.
Novel Agents May Change Paradigm for Advanced HER2+ Breast Cancer
The treatment of patients with advanced HER2-positive breast cancer could be reshaped in the next several years as clinical trials of several exciting new drugs begin to yield results.
Excitement Grows About Immunotherapy Potential in Breast Cancer
Although the first checkpoint inhibitor has just been approved for patients with breast cancer, findings from dozens of ongoing studies may eventually change the paradigm for large subsets of those with the malignancy.
Antibody-Drug Conjugates Make Headway in TNBC
The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.
Awareness Critical for Identifying irAEs Early in Breast Cancer
With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.
Promising Debut for PARP Inhibitors Spurs Excitement for Future Therapy
The introduction of PARP inhibitors into the breast cancer treatment paradigm is a clinically meaningful advance for patients with germline
mutations but much more research must be conducted to optimize their use.
Addition of Alpelisib Prolongs PFS in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer Subgroups
The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a
CDK4/6 Inhibitors Play a Growing Role in Enhancing Endocrine Therapy
For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.
Treatment Tailoring Possible With Gene Expression Profiling
Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay.
Getting It Right in Breast Cancer Means Being More Precise
After nearly 30 years as a breast cancer surgeon, Patrick I. Borgen, MD, finds that the most enduring theme in the field is constant change.
Top Developments in Breast Cancer Research Shape the MBCC Agenda
The breast cancer field is experiencing rapid advancements in the understanding of disease biology and the development of novel therapeutic strategies for several subtypes, with a clear direction toward personalized or precision medicine.
Intraoperative Shave Technique Proves Effective in Breast-Conserving Surgery
Data from the SHAVE and SHAVE2 trials, in terms of long-term outcomes vis-à-vis local recurrence, may lend some insight into the impact of adjuvant therapy on reducing the ramifications of a positive margin.
FDA Approvals in Myeloma and ITP, Applications Accepted in Myeloma and More
Dr. Shadman on the CLL14 Trial in CLL
Expert Highlights Need for Widespread Liquid Biopsy Use in Lung Cancer Treatment
Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer
Evaluating Surgery and Angiogenesis Inhibition in Recurrent Ovarian Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.